Millennium Management Updates Aclaris Therapeutics Stake

Ticker: ACRS · Form: SC 13G/A · Filed: Feb 1, 2024 · CIK: 1557746

Aclaris Therapeutics, INC. SC 13G/A Filing Summary
FieldDetail
CompanyAclaris Therapeutics, INC. (ACRS)
Form TypeSC 13G/A
Filed DateFeb 1, 2024
Risk Levellow
Pages5
Reading Time6 min
Key Dollar Amounts$0.00001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: institutional-ownership, amendment, hedge-fund, ownership-change

Related Tickers: ACRS

TL;DR

**Millennium Management just updated its Aclaris Therapeutics stake, watch for market reaction!**

AI Summary

Millennium Management LLC, a hedge fund, filed an amended SC 13G/A on February 1, 2024, disclosing its ownership of Aclaris Therapeutics, Inc. common stock as of December 31, 2023. This filing indicates a change in their beneficial ownership, which is important for investors as it shows a major institutional investor's updated position in Aclaris Therapeutics, potentially signaling their confidence or lack thereof in the company's future prospects.

Why It Matters

This filing reveals Millennium Management's updated investment in Aclaris Therapeutics, providing insight into a significant institutional investor's view of the company.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of ownership and does not inherently present a high risk, though changes in ownership can influence stock price.

Analyst Insight

Investors should monitor subsequent filings from Millennium Management LLC and Aclaris Therapeutics, Inc. to understand the full scope of any changes in ownership and its potential implications for the stock price.

Key Players & Entities

FAQ

What type of filing is this document?

This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.

Who is the reporting person in this filing?

The reporting person is Millennium Management LLC, a company incorporated in Delaware.

What is the subject company whose securities are being reported?

The subject company is Aclaris Therapeutics, Inc., with a CIK of 0001557746 and a business address at 701 Lee Road, Suite 103, Wayne, PA 19087.

What is the CUSIP number for the class of securities reported?

The CUSIP number for the common stock of Aclaris Therapeutics, Inc. is 00461U105.

What was the date of the event that required this filing?

The date of the event which required the filing of this statement was December 31, 2023.

Filing Stats: 1,543 words · 6 min read · ~5 pages · Grade level 10.3 · Accepted 2024-02-01 16:15:48

Key Financial Figures

Filing Documents

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a: (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) o An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) o An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); CUSIP No. 00461U105 SCHEDULE 13G Page 6 of 10 (g) o A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) o Group, in accordance with 240.13d-1(b)(1)(ii)(J).

Ownership

Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: See response to Item 9 on each cover page. (b) Percent of Class: See response to Item 11 on each cover page. (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote See response to Item 5 on each cover page. CUSIP No. 00461U105 SCHEDULE 13G Page 7 of 10 (ii) Shared power to vote or to direct the vote See response to Item 6 on each cover page. (iii) Sole power to dispose or to direct the disposition of See response to Item 7 on each cover page. (iv) Shared power to dispose or to direct the disposition of See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ .

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable.

Identification and Classification of the Subsidiary Which Acquired

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group See Exhibit I.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group Not applicable.

Certification

Item 10. Certification By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. 00461U105 SCHEDULE 13G Page 8 of 10 Exhibits: Exhibit I: Joint Filing Agreement, dated as of January 31, 2024, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. CUSIP No. 00461U105 SCHEDULE 13G Page 9 of 10 SIGNATURE After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct. Dated: January 31, 2024 MILLENNIUM MANAGEMENT LLC By: /s/Gil Raviv Name: Gil Raviv Title: Global General Counsel MILLENNIUM GROUP MANAGEMENT LLC By: /s/Gil Raviv Name: Gil Raviv Title: Global General Counsel /s/ Israel A. Englander Israel A. Englander CUSIP No. 00461U105 SCHEDULE 13G Page 10 of 10 EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.00001 per share, of Aclaris Therapeutics, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Dated: January 31, 2024 MILLENNIUM MANAGEMENT LLC By:

View Full Filing

View this SC 13G/A filing on SEC EDGAR

View on Read The Filing